We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App





Super-Potent Human Antibodies Protect Against COVID-19 in Animal Tests

By HospiMedica International staff writers
Posted on 17 Jun 2020
A team of scientists at Scripps Research (La Jolla, CA, USA) have isolated powerful coronavirus-neutralizing antibodies from COVID-19 patients and successfully tested them in animals, all in less than seven weeks.

The scientists discovered antibodies in the blood of recovered COVID-19 patients that provide powerful protection against SARS-CoV-2 when tested in animals and human cell cultures. More...
For their project, the scientists took blood samples from patients who had recovered from mild-to-severe COVID-19. Simultaneously, the team developed test cells that express ACE2, the receptor that SARS-CoV-2 uses to get into human cells. In a set of initial experiments, the team tested whether antibody-containing blood from the patients could bind to the virus and strongly block it from infecting the test cells.

The scientists were able to isolate more than 1,000 distinct antibody-producing immune cells, called B cells, each of which produced a distinct anti-SARS-CoV-2 antibody. The team obtained the antibody gene sequences from these B cells so that they could produce the antibodies in the laboratory. By screening these antibodies individually, the team identified several that, even in tiny quantities, could block the virus in test cells, and one that could also protect hamsters against heavy viral exposure. All of this work—including the development of the cell and animal infection models, and studies to discover where the antibodies of interest bind the virus—was completed in less than seven weeks. If further safety tests in animals and clinical trials in people go well, then conceivably the antibodies could be used in clinical settings as early as next January, the researchers say.

“The discovery of these very potent antibodies represents an extremely rapid response to a totally new pathogen,” said study co-senior author Dennis Burton, PhD, the James and Jessie Minor Chair in Immunology in the Department of Immunology & Microbiology at Scripps Research.

In the course of their attempts to isolate anti-SARS-CoV-2 antibodies from the COVID-19 patients, the researchers found one that can also neutralize SARS-CoV, the related coronavirus that caused the 2002-2004 outbreak of severe acute respiratory syndrome (SARS) in Asia.

“That discovery gives us hope that we will eventually find broadly neutralizing antibodies that provide at least partial protection against all or most SARS coronaviruses, which should be useful if another one jumps to humans,” added Burton.

Related Links:
Scripps Research


Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Multi-Chamber Washer-Disinfector
WD 390
Resorbable Bovine Collagen Membrane
GenDerm
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image:The NCIBT team with the cath lab members celebrating the completion of the study. (Image Credit: UC Davis)

Dual-Imaging Catheter Completes Initial Human Evaluation of Coronary Plaque

Atherosclerosis involves plaque buildup in arterial walls that can narrow blood vessels and increase the risk of heart attack, stroke, and other serious cardiovascular conditions. In coronary arteries,... Read more

Patient Care

view channel
Image: Researchers evaluated the Omni 128 cm long-axial field-of-view PET/CT system, which captures more of the body and radiotracer signal at once, potentially enabling shorter scans. (Photo courtesy of GE HealthCare)

Total-Body PET/CT Scanner Enables One-Minute Diagnostic-Quality Cancer Imaging

Positron emission tomography/computed tomography (PET/CT) combines radiotracer-based functional imaging with anatomical detail to diagnose, stage, and monitor cancer. Conventional scanners image the body... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: Steris is expanding its healthcare consumables portfolio through an agreement to acquire Xodus Medical, a surgical products business focused on patient and operating room staff safety.

Steris to Expand Surgical Safety Portfolio With $2.1 Billion Xodus Medical Deal

Steris has signed a definitive agreement to acquire Xodus Medical, a specialty surgical products business based in Pennsylvania, for $2.1 billion at closing. The acquisition will expand Steris’s healthcare... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.